Literature DB >> 16980881

A reappraisal of isoproterenol in goal-directed therapy of septic shock.

Marc Leone1, Ioanna Boyadjiev, Emile Boulos, Francois Antonini, Pierre Visintini, Jacques Albanèse, Claude Martin.   

Abstract

The goal of the study was to evaluate the effect of isoproterenol prescribed in goal-directed therapy for septic shock. Out of a cohort of 89 patients with septic shock, 14 patients treated with fluid and norepinephrine had inappropriate mixed venous oxygen saturation (SvO2<70%) not responding to correction of hypoxemia and anemia (>8 g.dL-1). Isoproterenol administration was started at a dose of 0.04 microg.kg-1.minute-1 with 0.025 microg.kg-1.minute-1 increments every 30 minutes until SvO2 was greater than 70%. Mean arterial pressure was maintained>or=65 mm.Hg by adjusting the norepinephrine infusion. Hemodynamic, oxygen, and renal variables were collected during a 12-h period. Patients with a known prior history of coronary disease were not eligible. Isoproterenol administration increased significantly SvO2 (62%+/-10% to 71%+/-9%), cardiac index (3.1+/-0.6 to 4.4+/-1.4 L.min-1.m-2), stroke index (27+/-3.4 to 38+/-6.1 mL.m-2), and left ventricular stroke work index (24+/-3.4 to 40+/-5.0 g.m-1.m-2). Heart rate rise did not reach a significant level. Arterial lactate concentration decreased significantly during the study period (5.7+/-2.8 to 3.4+/-1.6 mmol.L-1). No cardiac adverse events occurred with any electrocardiographic aspects of myocardial ischemia. This study suggests that isoproterenol is efficient to improve hemodynamics and oxygen variables in septic shock patients. There is a need for future investigations in larger groups of patients to determine whether isoproterenol can be an alternative to dobutamine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980881     DOI: 10.1097/01.shk.0000226345.55657.66

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  9 in total

1.  Isoproterenol infusion and microcirculation in septic shock.

Authors:  S Wiramus; J Textoris; R Bardin; C Vigne; C Kelway; C Martin; M Leone
Journal:  Heart Lung Vessel       Date:  2014

2.  Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.

Authors:  Christian Radke; Dagmar Horn; Christian Lanckohr; Björn Ellger; Michaela Meyer; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 3.  Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both?

Authors:  Konstantinos Drosatos; Anastasios Lymperopoulos; Peter Johannes Kennel; Nina Pollak; P Christian Schulze; Ira J Goldberg
Journal:  Curr Heart Fail Rep       Date:  2015-04

4.  High central venous oxygen saturation in the latter stages of septic shock is associated with increased mortality.

Authors:  Julien Textoris; Louis Fouché; Sandrine Wiramus; François Antonini; Sowita Tho; Claude Martin; Marc Leone
Journal:  Crit Care       Date:  2011-07-26       Impact factor: 9.097

5.  Isoproterenol infusion in septic shock.

Authors:  Viroj Wiwanitkit
Journal:  Heart Lung Vessel       Date:  2015

6.  No coronary artery occlusion in septic shock: Isoproterenol infusion should not be discouraged.

Authors:  Marc Leone; Claude Martin
Journal:  Heart Lung Vessel       Date:  2015

Review 7.  Central venous oxygenation: when physiology explains apparent discrepancies.

Authors:  Pierre Squara
Journal:  Crit Care       Date:  2014-11-10       Impact factor: 9.097

8.  Chlorogenic acid prevents isoproterenol-induced DNA damage in vascular smooth muscle cells.

Authors:  Jingshuai Wang; Jiyang Li; Jie Liu; Mengjiao Xu; Xiaowen Tong; Jianjun Wang
Journal:  Mol Med Rep       Date:  2016-09-15       Impact factor: 2.952

Review 9.  Shock - Classification and Pathophysiological Principles of Therapeutics.

Authors:  Olga N Kislitsina; Jonathan D Rich; Jane E Wilcox; Duc T Pham; Andrei Churyla; Esther B Vorovich; Kambiz Ghafourian; Clyde W Yancy
Journal:  Curr Cardiol Rev       Date:  2019
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.